Lansdale, PA-January 26, 2009: CRF Inc. (CRF), a leading global provider of electronic Patient Reported Outcomes (ePRO) and wireless data collection solutions for the Life Science Industry, today announced it has a new investor, smac | partners.
This announcement adds to a strong year of growth for CRF Inc., with several high profile new client wins for CRF Inc., in addition to its repeat business wins and the appointment of a new CEO, Rachael King.
Chief Executive, Rachael King said, "smac | partners will make a great addition to the CRF Inc. investment board. It has an impressive operational background and an exceptional global network and will add value to the strong investment team already with CRF Inc. 2008 has been an exceptional year for CRF Inc. and we look forward to continuing this innovation and growth throughout 2009."
smac | partners is a venture capital investor specialized in the ICT segment and is based in Munich, Germany. Oliver Kolbe, Managing Partner and Co-Founder of smac | partners, commented, "CRF is in a strong market position and its innovative approach to its solutions fits in perfectly with the smac | partners investment strategy, especially with the unique wireless service solution CRF Inc. offers to its clients."
In 2008 CRF also finalized its new global headquarters in Lansdale, PA, centralizing its services within North America.
About CRF Inc.
CRF Inc. ("CRF") is a leading global provider of electronic Patient Reported Outcomes ("ePRO") and wireless data collection solutions for the Life Science Industry. Through innovative technology and a thorough understanding of drug development and mobile computing, CRF is driving the change to safer and more efficient paper-free clinical trials. CRF's technology has been used by more than 180,000 patients across 59 countries in 60 languages for 45 indications. The company has demonstrated one of the
industry's highest patient compliance rates-an average 90% compliance through Phase I, II, III and IV clinical trials.
CRF's award-winning product, the TrialMaxR suite, is a flexible and configurable ePRO technology that provides real-time patient monitoring, outstanding data accuracy and increased safety through compliance. The TrialMax application's unique features enable clinical trial sponsors to rapidly collect valuable data and conduct complex clinical trials with greater flexibility than other ePRO solutions. CRF's experience, combined with its dedication to achieving the highest quality and most responsive customer service, has made the company one of the life science industry's most trusted partners.
For more information, please visit www.crfhealth.com
TrialMaxR, TrialCollectorR, TrialIntegratorR, TrialManagerR and TrialStudioR are registered trademarks of CRF Inc. All rights reserved. TrialLibraryT and other CRF product references are either a trademark or service mark of CRF Inc. All rights reserved. All other trademarks and/or service marks are the property of their respective owners.
About smac | partners
smac | partners is an international Venture Capital company, based in Munich, focusing on investments in young, fast growing companies in the IT-industry and telecommunication. smac partners is one of the few Venture Capital companies with long investment, management and exit experience in USA, China, India, Europe and Israel.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.